Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Bayer CEO Joins German Chancellor on China Visit, Announces New Investments
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company...
GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria
GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive...
Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial
Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...
Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development
Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...
Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC
Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID
CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has...
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...
Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care
Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a...
Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment
Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in...
Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has...
Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...
Kintor Pharmaceutical’s GT20029 Meets Primary Endpoint in Phase II AGA Trial
Kintor Pharmaceutical Ltd (HKG: 9939), a clinical-stage biotechnology company, has announced that its Phase II...
Jiangsu Hengrui Pharmaceuticals Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released...
China’s CDE Issues Guidelines for Pediatric Drug Labeling Updates
China’s Center for Drug Evaluation (CDE) has issued a notice outlining the “Detailed Rules for...
GSK’s Shingrix Vaccine Maintains High Efficacy for Over a Decade, Phase III Data Show
GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK), the UK-based pharmaceutical giant, has this week released long-term...
AbbVie’s Rinvoq Meets Main Goal in Late-Stage Giant Cell Arteritis Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that a late-stage clinical trial...